Loading…
Fate Therapeutics, Inc. is projected to rise to $3.59 by 2027, a +47% move from its current price of $2.45. FATE is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $2.34 | $2.45 | $2.57 | +0.14% |
| Aug 4 | $2.30 | $2.46 | $2.62 | +0.27% |
| Aug 5 | $2.27 | $2.46 | $2.66 | +0.41% |
| Aug 6 | $2.25 | $2.46 | $2.70 | +0.54% |
| Aug 7 | $2.23 | $2.47 | $2.73 | +0.68% |
| Aug 8 | $2.21 | $2.47 | $2.76 | +0.82% |
| Aug 9 | $2.19 | $2.47 | $2.79 | +0.95% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.19 | $2.47 | $2.79 | +0.95% |
| Week 2 | $2.10 | $2.50 | $2.96 | +1.91% |
| Week 3 | $2.04 | $2.52 | $3.11 | +2.88% |
| Week 4 | $2.00 | $2.54 | $3.24 | +3.86% |
| Week 5 | $1.96 | $2.57 | $3.37 | +4.85% |
| Week 6 | $1.93 | $2.59 | $3.49 | +5.85% |
| Week 7 | $1.90 | $2.62 | $3.60 | +6.86% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company develops CAR-targeted NK and T-cell product candidates, including FT836 which is in preclinical stage for multiple tumor types; and FT522 to treat B-cell Lymphoma and autoimmunity.
Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839 to treat complex autoimmune diseases, and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd.
for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
Fate Therapeutics (FATE) is trading at $2.51 per share, with a market capitalization of $292.56M, and it ranks 3308. The current price sits within a forecast where the average price is projected to move higher in the coming years, with 2026 showing an average of $2.51 and longer-run expectations of $5.11 by 2030, $18.92 by 2040, and $37.74 by 2050. The forecast also shows a maximum of $8.50 by 2030, $39.11 by 2040, and $86.80 by 2050, reflecting a bullish long-run outlook.
A major floor 53.9% below — a decisive break under it would weaken the trend.
The nearest floor, 23.7% below — buyers have tended to step in here.
The nearest ceiling, 26.9% above — a clean break opens room to run.
A major ceiling 51.7% above — clearing it would confirm fresh momentum.
Key FATE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of FATE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.41 | Buy | $2.45 | Sell |
| MA 10 | $2.52 | Sell | $2.52 | Sell |
| MA 20 | $2.74 | Sell | $2.57 | Sell |
| MA 50 | $2.44 | Buy | $2.40 | Buy |
| MA 100 | $1.94 | Buy | $2.10 | Buy |
| MA 200 | $1.57 | Buy | $1.81 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.16 | Neutral |
| Stoch RSI (14) | 23.86 | Neutral |
| CCI (20) | -82.16 | Neutral |
| Williams %R (14) | -80.60 | Info |
| MACD (12,26,9) | -0.07 | Sell |
| ROC (12) | -18.06 | Sell |
| Bollinger %B (20,2) | 0.22 | Neutral |
| Stochastic %K (14) | 19.40 | Buy |
| TRIX (15) | 0.38 | Buy |
| Awesome (5,34) | -0.12 | Sell |
| Ultimate (7,14,28) | 37.07 | Neutral |
| Momentum (10) | -0.33 | Sell |
| Aroon Osc (25) | 36.00 | Buy |
| Hull MA (9) | 2.39 | Buy |
| ADX (14) | 16.33 | Neutral |
| ATR (14) | 0.10 | Info |
The 30-day technical picture is bullish overall. The RSI14 sits at 50, and near-term momentum is balanced around the midpoint. The stock trades above the 200-day average of $1.56, and near the 50-day average of $2.43, suggesting a constructive short-term bias.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.99 | $2.45 | $3.58 | 0% | Neutral | |
| $2.69 | $3.59 | $5.16 | +47% | Bullish | |
| $2.95 | $4.14 | $6.30 | +69% | Bullish | |
| $2.78 | $4.08 | $6.49 | +66% | Bullish | |
| $3.15 | $4.80 | $7.92 | +96% | Bullish | |
| $3.28 | $5.18 | $8.81 | +111% | Bullish | |
| $4.23 | $6.92 | $12.10 | +182% | Bullish | |
| $5.64 | $9.51 | $17.06 | +288% | Bullish | |
| $5.20 | $9.05 | $16.61 | +269% | Bullish | |
| $4.97 | $8.91 | $16.70 | +264% | Bullish | |
| $8.09 | $16.74 | $34.22 | +583% | Bullish | |
| $14.45 | $32.11 | $73.86 | +12.1x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.99 | $2.45 | $3.00 | +0.00% |
| September 2026 | $2.15 | $2.59 | $3.25 | +5.74% |
| October 2026 | $2.27 | $2.77 | $3.54 | +6.99% |
| November 2026 | $2.23 | $2.75 | $3.56 | -0.86% |
| December 2026 | $2.20 | $2.73 | $3.58 | -0.48% |
Click any year to see its month-by-month FATE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, FATE is projected to trade between $0.99 and $3.58, averaging $2.45 — a potential gain of 0% from today's $2.45. A consolidation phase looks the most probable path here.
Fate Therapeutics, Inc.'s 2027 outlook centres on $3.59, within a $2.69 to $5.16 range. That is up +47% on the projected 2026 average. That marks a +47% change versus current levels. Momentum favours further upside here.
By 2028, FATE could reach as high as $6.30, with a base case around $4.14 and support toward $2.95 — roughly +69% from $2.45. Buyers look set to stay in control over this stretch.
Expect FATE to range from $2.78 to $6.49 through 2029. The $4.08 average target implies a +66% move from current prices. That is -1% versus the projected 2028 average. Momentum favours further upside here.
The FATE price prediction for 2030 points to an average of $4.80 (low $3.15, high $7.92) — a potential gain of +96% on today's $2.45. Buyers look set to stay in control over this stretch.
In 2031, FATE is projected to trade between $3.28 and $8.81, averaging $5.18 — a potential gain of +111% from today's $2.45. That is up +8% on the projected 2030 average. Momentum favours further upside here.
Fate Therapeutics, Inc.'s 2032 outlook centres on $6.92, within a $4.23 to $12.10 range. That is up +34% on the projected 2031 average. That marks a +182% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, FATE could reach as high as $17.06, with a base case around $9.51 and support toward $5.64 — roughly +288% from $2.45. Momentum favours further upside here.
Expect FATE to range from $5.20 to $16.61 through 2034. The $9.05 average target implies a +269% move from current prices. That is -5% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The FATE price prediction for 2035 points to an average of $8.91 (low $4.97, high $16.70) — a potential gain of +264% on today's $2.45. Momentum favours further upside here.
In 2040, FATE is projected to trade between $8.09 and $34.22, averaging $16.74 — a potential gain of +583% from today's $2.45. That is up +88% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Fate Therapeutics, Inc.'s 2050 outlook centres on $32.11, within a $14.45 to $73.86 range. That is up +92% on the projected 2040 average. That marks a +12.1x change versus current levels. Momentum favours further upside here.
Investing $1,000 in FATE today (≈ 408.163265 FATE) could be worth
$13,108.02
+$12,108.02 (+1211%) by 2050 · US Dollar
Based on the average projected FATE price of $32.11 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in FATEwould be worth at today's price.
$1,000 invested in FATE on Jul 31, 2025 (≈ 909.090889 FATE) would be worth
$2,227.27
+$1,227.27 (+122.7%) today · 2.23× · US Dollar
Based on a FATE entry price of $1.1 vs. today's $2.45.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.41 | $1,016.6 | +1.7% |
| 1 month ago | $3.02 | $811.26 | -18.9% |
| 3 months ago | $1.53 | $1,601.31 | +60.1% |
| 6 months ago | $1.23 | $1,991.87 | +99.2% |
| 1 year ago | $1.1 | $2,227.27 | +122.7% |
| All time (5.0y) ago | $83.25 | $29.43 | -97.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our FATE forecast.
Our base-case forecast reaches $4.90 around 2031.
Implied market cap at $4.90: $571.14M
The multi-year forecast shows a bullish trajectory with rising average prices across the period. In 2026 the average is $2.51, continuing into 2027 with an average of $3.73 and 2028 at $4.32, then 2029 at $4.30. By 2030 the average price is forecast at $5.11 with a 103.7% ROI and a bullish sentiment.
The forecast grows substantially in the 2040s, with 2040 averaging $18.92 and a 653.7% ROI, followed by 2050 averaging $37.74 with a 1,403.6% ROI. The outlook remains bullish through 2050, but these are estimates and not guarantees, and actual results will vary.
Tap a question to reveal the answer.
The 2030 forecast shows an average of $5.11 with a max of $8.50 and a min of $3.32, along with a 103.7% ROI and bullish sentiment.
The forecast indicates bullish sentiment from 2027 onward, with increasing average prices and notable ROIs: 2030 (avg $5.11, ROI 103.7%), 2040 (avg $18.92, ROI 653.7%), and 2050 (avg $37.74, ROI 1,403.6%).
Yes. The 2040 max is $39.11, and the 2050 max is $86.80, so the longer-term forecast includes values above $40.
Current price is $2.51 and market cap is $292.56M.
The 30-day range is $1.84 to $3.42. The sentiment is BULLISH, RSI is 50, with SMA50 at $2.43 and SMA200 at $1.56. Support is $1.87 and resistance is $3.11.
Fate Therapeutics, Inc. Community Discussion
0Share your Fate Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.